BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3428 related articles for article (PubMed ID: 7267338)

  • 1. [Stage I malignant melanoma of the skin. Prognostic value of thickness and level (author's transl)].
    Palangié A; Lassau F; Moreau T; Noury-Duperrat G; Cottenot F
    Nouv Presse Med; 1981 Jun; 10(28):2337-41. PubMed ID: 7267338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Survival analysis in patients with cutaneous malignant melanoma].
    Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
    Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depth of invasion and tumor thickness in primary cutaneous malignant melanoma. A study of 2012 cases.
    Søndergaard K
    Acta Pathol Microbiol Immunol Scand A; 1985 Mar; 93(2):49-55. PubMed ID: 3984735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
    Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
    Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
    Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
    Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic variables and prognostic groups for malignant melanoma. The information from Cox and Classification And Regression Trees analysis: an Italian population-based study.
    Crocetti E; Mangone L; Lo Scocco G; Carli P
    Melanoma Res; 2006 Oct; 16(5):429-33. PubMed ID: 17013092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Juvenile malignant melanoma.
    Reintgen DS; Vollmer R; Seigler HF
    Surg Gynecol Obstet; 1989 Mar; 168(3):249-53. PubMed ID: 2919354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic variables for patients with stage III malignant melanoma.
    Messaris GE; Konstadoulakis MM; Ricaniadis N; Leandros E; Androulakis G; Karakousis PC
    Eur J Surg; 2000 Mar; 166(3):233-9. PubMed ID: 10755339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.
    Rossi CR; Mocellin S; Pasquali S; Pilati P; Nitti D
    Ann Surg Oncol; 2008 Jan; 15(1):310-5. PubMed ID: 17987346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of biopsy on the prognosis of cutaneous melanoma of the head and neck.
    Austin JR; Byers RM; Brown WD; Wolf P
    Head Neck; 1996; 18(2):107-17. PubMed ID: 8647675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.
    Barnhill RL; Fine JA; Roush GC; Berwick M
    Cancer; 1996 Aug; 78(3):427-32. PubMed ID: 8697387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma].
    Keijzer R; Bril H; van der Loo EM; de Graaf PW
    Ned Tijdschr Geneeskd; 2004 May; 148(18):884-8. PubMed ID: 15152391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Independent prognostic importance of vascular invasion in nodular melanomas.
    Straume O; Akslen LA
    Cancer; 1996 Sep; 78(6):1211-9. PubMed ID: 8826942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival.
    Karjalainen JM; Eskelinen MJ; Kellokoski JK; Reinikainen M; Alhava EM; Kosma VM
    Br J Cancer; 1999 Feb; 79(5-6):895-902. PubMed ID: 10070887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?
    Nahabedian MY; Tufaro AP; Manson PN
    Ann Plast Surg; 2003 Jun; 50(6):601-6. PubMed ID: 12783009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, histological and quantitative prognostic factors in cutaneous malignant melanoma.
    Karjalainen J; Eskelinen M; Kosma VM; Lipponen P; Tuominen L; Alhava E
    Anticancer Res; 1992; 12(5):1507-11. PubMed ID: 1444213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
    McKenna DB; Lee RJ; Prescott RJ; Doherty VR
    Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
    Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
    Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors.
    Lindholm C; Andersson R; Dufmats M; Hansson J; Ingvar C; Möller T; Sjödin H; Stierner U; Wagenius G;
    Cancer; 2004 Nov; 101(9):2067-78. PubMed ID: 15372475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry.
    Eigentler TK; Buettner PG; Leiter U; Garbe C;
    J Clin Oncol; 2004 Nov; 22(21):4376-83. PubMed ID: 15514379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 172.